Company Filing History:
3 out of 896 
2 out of 233 
1 out of 1,164 
Years Active: 1997-2016
Title: The Innovative Contributions of Subburaman Mohan
Introduction
Subburaman Mohan, based in Redlands, California, is an accomplished inventor with a remarkable portfolio of five patents. His pioneering research primarily focuses on the field of osteogenic gene therapy, which aims to enhance bone growth and wound healing, particularly in the context of fracture repair. Subburaman’s work is recognized for its potential to revolutionize treatment methods in regenerative medicine.
Latest Patents
One of Subburaman's latest patents is centered around compositions and methods for osteogenic gene therapy. This patent includes recombinant nucleic acids that promote bone growth, particularly through the encoding of a fibroblast growth factor-2 (FGF-2) analog. The innovations described involve various vectors and cells incorporating these nucleic acids, as well as methods for enhancing bone regeneration and wound repair. Additionally, the patent details a mouse model for bone marrow transplantation, methods to induce hematopoietic stem cell differentiation, and techniques to enhance bone growth and fracture repair.
Career Highlights
Subburaman Mohan has worked with esteemed organizations, including the United States Government, as represented by the Department of Veterans Affairs, and Loma Linda University. His contributions in these roles have significantly advanced the understanding and application of gene therapy in bone regeneration.
Collaborations
Throughout his career, Subburaman has collaborated with notable colleagues such as David J. Baylink and Kin-Hing William Lau. These partnerships have led to enhanced research outcomes and have fostered advancements in the field of osteogenic therapy.
Conclusion
In summary, Subburaman Mohan is a leading inventor whose work in osteogenic gene therapy demonstrates significant potential for medical advancements. His contributions not only embody the spirit of innovation but also open new avenues for research and treatment in regenerative medicine. With a robust patent portfolio, Subburaman continues to be a pivotal figure in his field.